Company news

TherapeuticsMD, Inc. news in 2022

TherapeuticsMD, Inc.'s news releases, calls and decks from 2022, newest first.

View company

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

December 3, 2022

TherapeuticsMD Announces Third Quarter 2022 Financial Results

November 13, 2022

TherapeuticsMD Announces Additional $7 Million Private Placement

October 30, 2022

TherapeuticsMD Announces $7 Million Private Placement

October 2, 2022

TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

September 11, 2022

TherapeuticsMD Announces Second Quarter 2022 Financial Results

August 14, 2022

TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

August 7, 2022

TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

July 31, 2022

TherapeuticsMD Announces Expiration of Tender Offer

July 12, 2022

TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD

May 30, 2022

TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®

May 19, 2022

TherapeuticsMD Announces First Quarter 2022 Financial Results

May 15, 2022

TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022

May 9, 2022

TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million

April 13, 2022

TherapeuticsMD Announces Fourth Quarter 2021 Financial Results

March 9, 2022

TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx

March 6, 2022

TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022

February 28, 2022

Calls in 2022

Decks in 2022